A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model

Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Hui-Yen, Tyan, Yeu-Sheng, Hwang, Jeng-Jong, Shih, Kuang-Chung, Lin, Wei-Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933744/
https://www.ncbi.nlm.nih.gov/pubmed/33692869
http://dx.doi.org/10.3892/ol.2021.12598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933744/
https://www.ncbi.nlm.nih.gov/pubmed/33692869
http://dx.doi.org/10.3892/ol.2021.12598

Ejemplares similares